DDEA Board of Directors
Danish Diabetes and Endocrine Academy (DDEA) is headed by a Board of Directors (BoD) of seven members with a well-balanced and broad representation of stakeholders with regard to gender, age, national geography, and sector.
Members' profile and competences
The BoD includes representation from early-career researchers, senior researchers, and clinicians, as well as universities, hospitals, and life science industry, across diabetes and other endocrinology fields.
The members have competence and experience as board members/chairpersons, researchers, or clinicians in diabetes and other endocrinology fields, education and talent development, innovation and entrepreneurship, fundraising, public-private partnerships, impact assessment, and Novo Nordisk Foundation-funded initiatives and strategies.
- Defining and deciding the overall strategy and the strategy for DDEA’s four key activity classes and oversee its implementation, including approving the annual accounts and budget, the annual programme for the DDEA activities, and making the final decision on grant allocations.
- Performing an annual evaluation of DDEA and its organisation, including impact assessment of the success criteria, key performance indicators and other evaluation factors to decide whether the strategy for future activities needs adjusting.
Further information can be found in the Terms of References of the DDEA Board of Directors.
Chairman of the Board of Directors (BoD) of DDA (per January 1th, 2023 of DDEA) and BoD Member of the European Association for the Study of Diabetes (EASD) and the Bagger-Sørensen Foundation
MD, PhD, DMSc
Chief Physician and Head of Research, Steno Diabetes Center Odense, Odense University Hospital, and Clinical Professor in Endocrinology, University of Southern Denmark
Lise Wogensen Bach
Vice-Dean of Education, Faculty of Health, Aarhus University
Associate Professor, Aalborg University, and Senior Registrar, Aalborg University Hospital
Resident, Bispebjerg Hospital, and Postdoc, Rigshospitalet
Political Chief Research and Innovation, the Danish Association of the Pharmaceutical Industry
Scientific Director, the Novo Nordisk Foundation
Managing Director, Danish Diabetes and Endocrine Academy